Gilead Sciences
(NQ:
GILD
)
67.55
+0.86 (+1.29%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
5,746,984
Open
67.86
Bid (Size)
67.55 (1)
Ask (Size)
67.72 (2)
Prev. Close
66.69
Today's Range
67.03 - 68.18
52wk Range
62.07 - 87.86
Shares Outstanding
1,253,809,440
Dividend Yield
4.44%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
This Domino's Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Today 9:38 EDT
Via
Benzinga
Amgen, Inc. Dividend Stock Analysis
July 05, 2024
Amgen Inc. is one of the world's leading biotech companies with major treatments for anemia, neutropenia, rheumatoid and psoriatic arthritis, psoriasis, cancer and osteoporosis.
Via
Talk Markets
Performance
YTD
-18.85%
-18.85%
1 Month
+3.52%
+3.52%
3 Month
-2.69%
-2.69%
6 Month
-19.57%
-19.57%
1 Year
-10.75%
-10.75%
More News
Read More
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
July 04, 2024
Via
InvestorPlace
Exposures
Product Safety
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
July 04, 2024
Via
InvestorPlace
Key Takeaways From Gilead Sciences Analyst Ratings
July 01, 2024
Via
Benzinga
3 Magnificent Stocks Retirees Can Buy and Hold Forever
July 01, 2024
Via
The Motley Fool
Gilead Sciences's Options Frenzy: What You Need to Know
June 24, 2024
Via
Benzinga
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
June 28, 2024
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
June 25, 2024
Via
Benzinga
7 Dividend Stocks to Buy Now: June 2024
June 23, 2024
Via
InvestorPlace
DraftKings And Dell Were Among The 10 Biggest Large Cap Stock Gainers Last Week (June 16-June 22): Are These In Your Portfolio?
June 23, 2024
Via
Benzinga
MarketBeat Week in Review – 6/17 - 6/21
June 22, 2024
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Top Analyst Reports For Abbott, BP & Gilead
June 21, 2024
Via
Talk Markets
Nvidia Snaps 8-Week Winning Run, S&P 500 Marks Longest Streak Without A 2% Drop Since Great Recession, Oil Prices Stage Comeback: This Week In The Market
June 21, 2024
Via
Benzinga
Topics
Economy
Stocks
Exposures
Economy
US Equities
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
June 21, 2024
Via
Benzinga
Why Gilead Sciences Stock Is Trading Higher Friday
June 21, 2024
Via
Benzinga
Pre-Market Movers - June 21, 2024
June 21, 2024
Via
Talk Markets
Gilead Sciences Stock Surges on HIV Treatment Trial Success
June 21, 2024
Via
MarketBeat
Exposures
Product Safety
Defying the Norms: 3 High P/E Stocks With Room to Run
June 21, 2024
Via
InvestorPlace
S&P 500, Nasdaq 100 Dip From Record Highs As Investors Take Chipmaker Profits; Energy Sector Rebounds, Yields Rise: What's Driving Markets Thursday?
June 20, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Gilead Flashes A Bullish Sign After HIV Drug Proves 100% Effective
June 20, 2024
Via
Investor's Business Daily
Why Is Gilead Sciences Stock Trading Higher On Thursday?
June 20, 2024
Via
Benzinga
KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday
June 20, 2024
Via
Benzinga
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention
June 20, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
June 20, 2024
Via
FinancialNewsMedia
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.